Comparison of the cross-reactive anti-influenza neutralizing activity of polymeric and monomeric IgA monoclonal antibodies

Viral Immunology

Volumn 25, Issue 5, 2012, Pages 433-439

  Tanimoto, Takeshi ^b   Haredy, Ahmad M ^a,b   Takenaka, Nobuyuki ^a   Tamura, Shin Ichi ^c   Okuno, Yoshinobu ^b   Mori, Yasuko ^a,d   Yamanishi, Koichi ^a   Okamoto, Shigefumi ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; INFLUENZA VACCINE; MONOMERIC IMMUNOGLOBULIN A ANTIBODY; PERTUSSIS TOXIN; POLYMERIC IMMUNOGLOBULIN A ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL FILTRATION; HEMAGGLUTINATION INHIBITION TEST; IMMUNOASSAY; INFECTION PREVENTION; INFLUENZA A (H3N2); INFLUENZA VIRUS A H3N2; MOUSE; NONHUMAN; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; FEMALE; IMMUNOGLOBULIN A; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PERTUSSIS TOXIN; SEQUENCE ANALYSIS, RNA;

MUS; ORTHOMYXOVIRIDAE;

EID: 84867191074     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2012.0026     Document Type: Article

References (30)

1. Armstrong SJ, and Dimmock NJ: Neutralization of influenza virus by low concentrations of hemagglutinin-specific polymeric immunoglobulin A inhibits viral fusion activity, but activation of the ribonucleoprotein is also inhibited. J Virol 1992;66:3823-3832.
2. Belshe RB: Current status of live attenuated influenza virus vaccine in the US. Virus Res 2004;103:177-185.
3. Clements ML, Betts RF, Tierney EL, and Murphy BR: Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986;24:157-160.
4. Dhepakson P, Mori Y, Jiang YB, et al.: Human herpesvirus-6 rep/U94 gene product has single-stranded DNA-binding activity. J Gen Virol 2002;83:847-854.
5. Hoffmann E, Stech J, Guan Y, Webster RG, and Perez DR: Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 2001;146:2275-2289.
6. Kikuta K, Hirabayashi Y, Nagamine T, et al.: Cross-protection against influenza B type virus infection by intranasal inoculation of the HA vaccines combined with cholera toxin B subunit. Vaccine 1990;8:595-599.
7. Lamm ME: Cellular aspects of immunoglobulin A. Adv Immunol 1976;22:223-290.
8. Mazanec MB, Nedrud JG, and Lamm ME: Immunoglobulin A monoclonal antibodies protect against Sendai virus. J Virol 1987;61:2624-2626.
9. Mestecky J, McGhee JR: Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv Immunol 1987;40:153-245.
10. Moldoveanu Z, Clements ML, Prince SJ, Murphy BR, and Mestecky J: Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 1995;13:1006-1012.
11. Nichol KL: The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003;21: 1769-1775.
12. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, and Hak E: Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007;357:1373-1381.
13. Okada J, Ohshima N, Kubota-Koketsu R, et al.: Localization of epitopes recognized by monoclonal antibodies that neutralized the H3N2 influenza viruses in man. J Gen Virol 2011;92:326-335.
14. Okamoto S, Matsuura M, Akagi T, et al.: Poly(gammaglutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice. Vaccine 2009;27:5896-5905.
15. Okamoto S, Yoshii H, Akagi T, et al.: Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity. Vaccine 2007;25:8270-8278.
16. Quan FS, Compans RW, Nguyen HH, and Kang SM: Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol 2008;82:1350-1359.
17. Renegar KB, Jackson GD, and Mestecky J: In vitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA. J Immunol 1998;160:1219-1223.
18. Renegar KB, Small PA Jr, Boykins LG, and Wright PF: Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 2004;173:1978-1986.
19. Rowe T, Abernathy RA, Hu-Primmer J, et al.: Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999;37:937-943.
20. Smirnov YA, Gitelman AK, Govorkova EA, Lipatov AS, and Kaverin NV: Influenza H5 virus escape mutants: immune protection and antibody production in mice. Virus Res 2004; 99:205-208.
21. Sorensen V, Rasmussen IB, Norderhaug L, Natvig I, Michaelsen TE, and Sandlie I: Effect of the IgM and IgA secretory tailpieces on polymerization and secretion of IgM and IgG. J Immunol 1996;156:2858-2865.
22. Tamura S, Funato H, Hirabayashi Y, et al.: Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Eur J Immunol 1991;21:1337-1344.
23. Tamura S, Hasegawa H, and Kurata T: Estimation of the effective doses of nasal-inactivated influenza vaccine in humans from mouse-model experiments. Jpn J Infect Dis 2010; 63:8-15.
24. Tamura S, Ito Y, Asanuma H, et al.: Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol 1992;149:981-988.
25. Tamura SI, Asanuma H, Ito Y, et al.: Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol 1992; 22:477-481.
26. Taylor HP, and Dimmock NJ: Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. J Exp Med 1985;161:198-209.
27. Tumpey TM, Renshaw M, Clements JD, and Katz JM: Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 2001;75:5141-5150.
28. Underwood PA: Mapping of antigenic changes in the haemagglutinin of Hong Kong influenza (H3N2) strains using a large panel of monoclonal antibodies. J Gen Virol 1982;62: 153-169.
29. Wagner DK, Clements ML, Reimer CB, Snyder M, Nelson DL, and Murphy BR: Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J Clin Microbiol 1987; 25:559-562.
30. Wright PF, Neuman G, and Kawaoka Y: Orthomyxoviruses, In: Fields Virology, 5th ed. (Knipe DM, Howley PM, Grifin DE, Martin MA, Ramb RA, Roizman B, and Straus SE, eds.). Lippincott-Raven, Philadelphia, 2007, pp. 1691-1740.